Blood safety is changing
Safe donated blood is critical to improving certain patient outcomes.
Transfusion-transmitted infectious (TTI) risk has greatly reduced due to current testing measures; yet, residual risks exist such as those due to emerging pathogens and bacterial contamination.
The INTERCEPT Blood System, pathogen reduction system, a proactive approach to TTI risk reduction provides continued protection against TTIs through broad spectrum inactivation of viruses, bacteria, and parasites. T-cells are also reduced to levels that potentially lower the risk for transfusion-associated graft-versus-host disease (TA-GVHD) in platelet components.
INTERCEPT Blood System for Platelets and Plasma.
Recognized as a safe, effective and reliable choice of European blood centers for over a decade, INTERCEPT is now FDA approved, bringing the proven benefits of pathogen inactivation by reduction to the US.
